Toby Rogers, MD, associate professor of medicine at Georgetown University and an interventional cardiologist at MedStar, explains how electrosurgical procedures for transcaval access have helped large numbers of patients receive transcatheter heart valves who otherwise would have been disqualified due to anatomical issues.
Toby Rogers, MD, PhD, noted that BASILICA is a fairly complex procedure. Using this advanced technology, however, could make it easier to perform and improve patient access.
Dean J. Kereiakes, MD, was left paralyzed after battling severe orthopedic issues for his entire career. Back in the cath lab after a long recovery, he is now stressing the importance of workplace safety among interventional cardiologists.
Andreas Ruck, MD, discussed new registry data on Boston Scientific’s Acurate neo2 TAVR valve, comparing it to popular devices from Edwards Lifesciences and Medtronic.
Steven Bolling, MD, noted that tricuspid treatments have been linked to consistent benefits in terms of quality of life. However, he said, finding clear improvements in clinical outcomes has been more challenging.
Toby Rogers, MD, associate professor of medicine at Georgetown University and an interventional cardiologist at MedStar, explains how electrosurgical procedures for transcaval access have helped large numbers of patients receive transcatheter heart valves who otherwise would have been disqualified due to anatomical issues.
Toby Rogers, MD, PhD, noted that BASILICA is a fairly complex procedure. Using this advanced technology, however, could make it easier to perform and improve patient access.
Dean J. Kereiakes, MD, was left paralyzed after battling severe orthopedic issues for his entire career. Back in the cath lab after a long recovery, he is now stressing the importance of workplace safety among interventional cardiologists.
Andreas Ruck, MD, discussed new registry data on Boston Scientific’s Acurate neo2 TAVR valve, comparing it to popular devices from Edwards Lifesciences and Medtronic.
Steven Bolling, MD, noted that tricuspid treatments have been linked to consistent benefits in terms of quality of life. However, he said, finding clear improvements in clinical outcomes has been more challenging.
S. Chris Malaisrie, MD, professor of surgery at Northwestern University, explained what these data can tell us about the lifetime management of patients who require aortic valve replacement.
Bioresorbable stents are back in the spotlight thanks to some significant progress from multiple medtech companies. Eric Secemsky, MD, discussed some of the biggest breakthroughs in this space at CRT 2025.
Howard Herrmann, MD, MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.
